skip to main content

H413

H413

Catalogue No.

06092007

Cell Line Name

H413

Cell Line Description

Established from a squamous cell carcinoma (SCC) of the buccal mucosa (20mm-40mm) of a 53 year-old female patient. STNMP stage II, moderately differentiated, node negative tumour. Mutant p53, codon 68 exon 4, G to T; wild type K-, N- and Ha-ras. These cells are non-tumourigenic on subcutaneous injection into athymic nude mice, but tumourigenic on injection into the floor of the mouth.

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

TGFbeta type I receptor, TGFbeta II receptor, TGFbeta III receptor

Tissue of Origin

Buccal mucosa

Morphology

Polygonal

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D5S818: 12
D7S820: 9,10
D13S317: 12
D16S539: 11
TH01: 6,9.3
TPOX: 8,11
vWA: 16,20

Karyotype

Not specified

Disease

Squamous Cell Carcinoma

Culture Conditions

Cell Type

Epithelial-like

Subculture Routine

Split sub-confluent cultures (70-80%), approximately every 5-6 days, 1:8 to 1:10 using 0.05% trypsin/EDTA; 5% CO₂; 37°C. Suggested seeding density 5 x 1000 cells/cm². Cells can take approximately 10 minutes to detach, an alternative is to trypsinise 2 to 3 times with fresh trypsin for shorter periods for each trypsin application. Avoid knocking flasks during the trypsinisation process as this can lead to loss of viability.

Culture Medium

DMEM:HAMS F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS) + 0.5 ug/ml sodium hydrocortisone succinate

Growth Mode

Adherent

Additional Info

Depositor

Professor Stephen Prime, Department of Oral & Dental Science, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Prime et al., 1994; Int J Cancer 56, 406-412, Prime et al., 1990; J Pathol 160, 259-269, Prime et al., 1994 Br J Cancer 69, 8-15; Yeudall et al., 1993; Eur J Cancer B Oral Oncol 29B, 63-67 & 1995 31B 136-143

Bibliography

Not Available

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: H413 (ECACC 06092007).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.